Dark

Check out our API

MSON
Misonix Inc
stock NASDAQ

Inactive

Oct 28, 2021

26.54USD+4.736%(+1.20)158,811

Pre-market

0.00USD-100.000%(-25.34)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Oct 26, 2021

04:47PM EDT Bioventus, Misonix Reports Shareholders Approve Deal Benzinga

Oct 18, 2021

08:00AM EDT BIOVENTUS INC. and MISONIX, INC. Announce Election Deadline of GlobeNewswire Inc

Sep 2, 2021

04:02PM EDT Misonix Q4 Net Loss $4.473M vs $8.5M In Same Qtr. Last Year, Adj. EBITDA Loss $1.595M, Sales $19.68M Up From $13.71M YoY Benzinga

04:01PM EDT Misonix, Inc. (Nasdaq: MSON) (Misonix or the Company), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported unaudited financial results for the fiscal 2021 fourth quarter and full fiscal year ended June 30, 2021 as summarized below: GlobeNewswire Inc

Aug 3, 2021

07:55AM EDT The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business Benzinga

Aug 2, 2021

10:23AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2021 Benzinga

05:50AM EDT BTIG Downgrades Misonix to Neutral Benzinga

Jul 31, 2021

10:42AM EDT MISONIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Misonix, Inc. - MSON Business Wire

Jul 30, 2021

11:42AM EDT Craig-Hallum Downgrades Misonix to Hold, Raises Price Target to $28 Benzinga

10:56AM EDT Shares of minimally invasive therapeutic ultrasonic technologies and regenerative medicine provider Misonix, Inc. (MSON) are up more than 11% Friday morning at $26.45. RTTNews

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 30, 2021 Benzinga

07:54AM EDT The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs Benzinga

07:02AM EDT Bioventus Scoops Up Misonix In $518M Stock & Cash Deal; Raises FY21 Sales Outlook Benzinga

06:35AM EDT Canaccord Genuity Downgrades Misonix to Hold, Raises Price Target to $28 Benzinga

Jul 29, 2021

04:10PM EDT Bioventus Announced It Has Entered Into A Definitive Agreement To Acquire Misonix In A Cash-And-Stock Transaction. Misonix Stockholders Will Receive Either 1.6839 Shares Of Bioventus Class A Common Stock Or $28 In Cash Without Interest Per Held Share. Benzinga

04:07PM EDT Misonix, Bioventus Board Have Approved Merger Between Companies For ~$518M; Misonix Shareholders Will Have Right To Elect To Receive For Each Share Either 1.6839 Shares Of Bioventus Or $28/Share In Cash Benzinga

04:06PM EDT Misonix Sees Q4 Sales ~$19.7M vs $18.64M Estimate; FY21 Sales $74M vs $73M Est. Benzinga

Jun 17, 2021

08:33AM EDT The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme Benzinga

Jun 8, 2021

09:17AM EDT The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex Benzinga

Jun 4, 2021

09:39AM EDT The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact Benzinga

May 14, 2021

08:35AM EDT Misonix Appoints Patrick Beyer As An Independent Member Of Board RTTNews

08:30AM EDT Misonix, Inc. (Nasdaq: MSON) (Misonix or the Company), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced its Board of Directors has appointedPatrick J. Beyeras an independent member of the Board. Mr. Beyer joined the Board on May 12, 2021. GlobeNewswire Inc

May 10, 2021

01:30PM EDT Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that Chief Executive Officer, Stavros Vizirgianakis, along with Chief Financial Officer, Joe Dwyer, will be participating in the following upcoming virtual investor conferences in May and June: GlobeNewswire Inc

May 6, 2021

04:44PM EDT Misonix Q3 EPS $(0.22) Beats $(0.26) Estimate, Sales $18.35M Beat $18.04M Estimate Benzinga

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

04:17AM EDT Earnings Scheduled For May 6, 2021 Benzinga

May 5, 2021

10:07AM EDT Earnings Outlook For Misonix Benzinga

Apr 22, 2021

04:20PM EDT Misonix Inc Files For Mixed Shelf Of Up To $100M Benzinga

Apr 20, 2021

08:15AM EDT Misonix to Report Fiscal 2021 Third Quarter Financial Results and GlobeNewswire Inc

Mar 30, 2021

08:05AM EDT Misonix Expands Ultrasonic Technology Capabilities to Address the GlobeNewswire Inc

Mar 4, 2021

09:27AM EST Misonix Receives Health Canada Approval For neXus Ultrasonic Surgical System Benzinga

09:25AM EST Misonix Receives Health Canada Approval for neXus GlobeNewswire Inc

Mar 1, 2021

08:07AM EST Misonix to Participate in Upcoming March Investor Conferences GlobeNewswire Inc

Feb 11, 2021

10:00AM EST Misonix, Inc.(NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that Misonix Chief Executive Officer, Stavros Vizirgianakis, along with Joe Dwyer, Chief Financial Officer, will be participating in two upcoming investor conferences. GlobeNewswire Inc

Feb 9, 2021

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Feb 4, 2021

04:05PM EST Misonix Q2 EPS $(0.07) Beats $(0.30) Estimate, Sales $18.26M Beat $17.15M Estimate Benzinga

04:01PM EST Misonix, Inc. (Nasdaq: MSON) (Misonix or the Company), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported financial results for the fiscal 2021 second quarter ended December 31, 2020 as summarized below: GlobeNewswire Inc

08:35AM EST Earnings Scheduled For February 4, 2021 Benzinga

07:22AM EST The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs Benzinga

Jan 30, 2021

01:19PM EST The Week Ahead In Biotech: Merck, Pfizer In Earnings Mix, Plus Adamas, Mallinckrodt FDA Decisions, IPOs And More Benzinga

Jan 21, 2021

10:30AM EST Misonix to Report Fiscal 2021 Second Quarter Financial Results and GlobeNewswire Inc

Dec 23, 2020

08:30AM EST Misonix to Present at the 39th Annual J.P. Morgan Healthcare GlobeNewswire Inc

Dec 18, 2020

10:14AM EST Misonix Announces the Second Largest U.S. Commercial Payer Has GlobeNewswire Inc

Nov 23, 2020

10:00AM EST Misonix to Participate in the Piper Sandler 32nd Annual Virtual GlobeNewswire Inc

Nov 12, 2020

10:00AM EST Misonix to Participate at Upcoming Craig-Hallum and Canaccord GlobeNewswire Inc

Nov 5, 2020

04:25PM EST Misonix Q1 EPS $(0.29) Beats $(0.30) Estimate, Sales $17.73M Beat $17.34M Estimate Benzinga

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 20, 2020

10:00AM EDT Misonix to Report Fiscal 2021 First Quarter Financial Results and GlobeNewswire Inc

Oct 6, 2020

07:07AM EDT Misonix Reports Q1 Prelim. Sales of ~$17.7M, Beats $17.07M Est. Benzinga

07:00AM EDT Misonix, Inc. (Nasdaq: MSON) (Misonix, the Company, we, us or our), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced preliminary unaudited revenue for the first quarter of its fiscal year 2021 ended September 30, 2020. GlobeNewswire Inc

Sep 21, 2020

10:29AM EDT Misonix Enters Into Supply And Distribution Deal With Gunze For TheraGenesis Bilayer Wound Matrix RTTNews

10:01AM EDT Misonix Reports Exclusive Supply, Distribution Deal With Gunze Limited For TheraGenesis Bilayer Wound Matrix Benzinga

10:00AM EDT Misonix Enters Into Exclusive Supply and Distribution Agreement GlobeNewswire Inc

Sep 9, 2020

10:00AM EDT Misonix to Present at the Cantor Virtual Global Healthcare Conference GlobeNewswire Inc

Sep 3, 2020

04:20PM EDT Misonix: Q4 Earnings Insights Benzinga

04:06PM EDT Misonix Q4 Loss/share $0.50 Vs. Loss $0.25 Year Ago RTTNews

04:02PM EDT Misonix Q4 EPS $(0.50) Misses $(0.48) Estimate, Sales $13.71M Beat $9.51M Estimate Benzinga

04:01PM EDT Misonix, Inc. (Nasdaq: MSON) (Misonix or the Company), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported unaudited financial results for the fiscal 2020 fourth quarter and full fiscal year ended June 30, 2020 as summarized below: GlobeNewswire Inc

04:16AM EDT Earnings Scheduled For September 3, 2020 Benzinga

Sep 2, 2020

10:32AM EDT Preview: Misonix's Earnings Benzinga

Aug 30, 2020

08:24AM EDT The Week Ahead In Biotech (Aug. 30- Sept. 5): Bristol-Myers Squibb FDA Decision, Adcom Review For Glaxo, Amarin Vascepa Hearing Benzinga

Jul 30, 2020

08:01AM EDT Misonix to Present at the 40th Annual Canaccord Genuity Growth GlobeNewswire Inc

Share